UK markets open in 4 hours 59 minutes

NVAX Jan 2023 70.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.2500-1.1500 (-21.30%)
As of 01:02PM EDT. Market open.
Full screen
Previous close5.4000
Open4.3000
Bid4.0500
Ask4.3000
Strike70.00
Expiry date2023-01-20
Day's range4.0000 - 4.3000
Contract rangeN/A
Volume6
Open interest2.13k
  • Editor's pick
    Yahoo Finance

    U.S. to end purchase of COVID-19 vaccines as industry pivots to commercial market

    Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.

  • Zacks

    Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

    Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

  • Motley Fool

    Why Novavax Stock Eked Out a Gain Today

    The coronavirus might not pose the threat it once was, and Novavax (NASDAQ: NVAX) can be considered a laggard in the Great COVID-19 Vaccine Race, but the stock certainly has plenty of believers. The more important of these two filings was with the U.S. Food and Drug Administration (FDA). Novavax's money product of the moment, its coronavirus vaccine Nuvaxovid, won emergency use authorization (EUA) from the American regulator last month.